To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation.
作者信息
Aslibekyan Stella, Claas Steven A, Arnett Donna K
机构信息
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 55294-0022, USA.
出版信息
Circ Cardiovasc Genet. 2013 Aug;6(4):409-12; discussion 412. doi: 10.1161/CIRCGENETICS.112.000010.
Abstract
摘要
相似文献
1
To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation.
Circ Cardiovasc Genet. 2013 Aug;6(4):409-12; discussion 412. doi: 10.1161/CIRCGENETICS.112.000010.
2
Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.
Pharmacogenomics. 2012 May;13(7):831-40. doi: 10.2217/pgs.12.25.
3
Questions about genetic variation in 9p21 as a predictor of cardiovascular risk.
Ann Intern Med. 2009 May 19;150(10):736; author reply 737. doi: 10.7326/0003-4819-150-10-200905190-00020.
4
Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.
Indian J Med Res. 2019 Sep;150(3):261-271. doi: 10.4103/ijmr.IJMR_1209_17.
5
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Atherosclerosis. 2014 Jul;235(1):58-64. doi: 10.1016/j.atherosclerosis.2014.04.009. Epub 2014 Apr 26.
6
Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
Am J Cardiovasc Drugs. 2013 Apr;13(2):79-85. doi: 10.1007/s40256-013-0020-9.
7
Pharmacogenetic study of statin therapy and cholesterol reduction.
Curr Atheroscler Rep. 2005 May;7(3):177-8.
8
Pharmacogenomics of cholesterol-lowering therapy.
Vascul Pharmacol. 2006 Feb;44(2):75-89. doi: 10.1016/j.vph.2005.07.012. Epub 2005 Dec 5.
9
Pharmacogenomics of lipid-lowering therapies.
Pharmacogenomics. 2013 Jun;14(8):981-95. doi: 10.2217/pgs.13.71.
10
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Eur Heart J. 2012 Jan;33(2):165-75. doi: 10.1093/eurheartj/ehr239. Epub 2011 Jul 30.
引用本文的文献
1
The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.
Clin Transl Sci. 2025 May;18(5):e70239. doi: 10.1111/cts.70239.
2
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program.
Front Genet. 2023 Dec 13;14:1278215. doi: 10.3389/fgene.2023.1278215. eCollection 2023.
3
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
Clin Pharmacol Ther. 2021 Sep;110(3):723-732. doi: 10.1002/cpt.2355. Epub 2021 Aug 15.
4
Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area.
J Clin Med. 2020 Dec 24;10(1):34. doi: 10.3390/jcm10010034.
5
The Association of Aquaporin-1 Gene with Marathon Running Performance Level: a Confirmatory Study Conducted in Male Hispanic Marathon Runners.
Sports Med Open. 2020 Mar 20;6(1):16. doi: 10.1186/s40798-020-00243-0.
6
DNA methylome profiling of all-cause mortality in comparison with age-associated methylation patterns.
Clin Epigenetics. 2019 Feb 8;11(1):23. doi: 10.1186/s13148-019-0622-4.
7
Complex polymorphisms in endocytosis genes suggest alpha-cyclodextrin as a treatment for breast cancer.
PLoS One. 2018 Jul 2;13(7):e0199012. doi: 10.1371/journal.pone.0199012. eCollection 2018.
8
Pharmacogenetics in Cardiovascular Medicine.
Curr Genet Med Rep. 2016 Sep;4(3):119-129. doi: 10.1007/s40142-016-0096-z. Epub 2016 Jun 16.
9
Genome-wide Association Study of Susceptibility to Particulate Matter-Associated QT Prolongation.
Environ Health Perspect. 2017 Jun 8;125(6):067002. doi: 10.1289/EHP347.
10
Single-Subject Studies in Translational Nutrition Research.
Annu Rev Nutr. 2017 Aug 21;37:395-422. doi: 10.1146/annurev-nutr-071816-064717. Epub 2017 Jul 17.
本文引用的文献
1
An integrated encyclopedia of DNA elements in the human genome.
Nature. 2012 Sep 6;489(7414):57-74. doi: 10.1038/nature11247.
2
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.
Atherosclerosis. 2011 Aug;217(2):458-64. doi: 10.1016/j.atherosclerosis.2011.06.023. Epub 2011 Jun 17.
3
Pharmacogenomics: the genetics of variable drug responses.
Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820.
4
The false-positive to false-negative ratio in epidemiologic studies.
Epidemiology. 2011 Jul;22(4):450-6. doi: 10.1097/EDE.0b013e31821b506e.
5
Genome-wide association studies in pharmacogenomics.
Nat Rev Genet. 2010 Apr;11(4):241-6. doi: 10.1038/nrg2751.
6
Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies.
Eur J Hum Genet. 2010 Jul;18(7):832-7. doi: 10.1038/ejhg.2010.26. Epub 2010 Mar 17.
7
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Pharmacogenet Genomics. 2010 Feb;20(2):77-85. doi: 10.1097/FPC.0b013e328333f70b.
8
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.
Circ Cardiovasc Genet. 2009 Apr;2(2):173-81. doi: 10.1161/CIRCGENETICS.108.818062. Epub 2009 Feb 12.
9
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Circ Cardiovasc Genet. 2008 Dec;1(2):100-6. doi: 10.1161/CIRCGENETICS.108.795013. Epub 2008 Dec 9.
10
Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization.
Circulation. 2009 Aug 18;120(7):553-9. doi: 10.1161/CIRCULATIONAHA.108.821082. Epub 2009 Aug 3.
Zotero 插件